Nigro protocol (mitomycin-C + 5-FU + RT, anal SCC)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-MITOMYCIN-C DRUG-5-FLUOROURACIL |
|---|
| ID | REG-NIGRO-MMC-5FU-RT |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-05-04 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | None declared |
Used By
Drug
DRUG-MITOMYCIN-C- Mitomycin C
Indication
IND-ANAL-SCC-LA-1L-NIGRO-CRT- IND-ANAL-SCC-LA-1L-NIGRO-CRT
Sources
SRC-ACT2-JAMES-2013- Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatm...